We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

75 hedge funds and large institutions have $17.1M invested in Cue Biopharma in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,450% more call options, than puts

Call options by funds: $279K | Put options by funds: $18K

1% more funds holding

Funds holding: 74 → 75 (+1)

5% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 20

0.26% less ownership

Funds ownership: 1.21% → 0.95% (-0.26%)

36% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 22

45% less capital invested

Capital invested by funds: $31M → $17.1M (-$13.9M)

Holders
75
Holders Change
+1
Holders Change %
+1.35%
% of All Funds
1.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
14
Reduced
22
Closed
20
Calls
$279K
Puts
$18K
Net Calls
+$261K
Net Calls Change
+$57K

Top Buyers

Rank Fund Capital Flow
1
GLA
Good Life Advisors
Pennsylvania
+$371K
2
Goldman Sachs
Goldman Sachs
New York
+$364K
3
YIH
Y-Intercept (HK)
Hong Kong
+$253K
4
Millennium Management
Millennium Management
New York
+$217K
5
BL
Bleichroeder LP
New York
+$176K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.45M
2
State Street
State Street
Massachusetts
-$961K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$571K
4
Renaissance Technologies
Renaissance Technologies
New York
-$518K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$415K
Name Holding Trade Value Shares
Change 		Change in
Stake
RhumbLine Advisers
51
RhumbLine Advisers
Massachusetts
$8.24K -$42.8K -865 -80%
GG
52
Gleason Group
Kentucky
$7.44K – – –
Citigroup
53
Citigroup
New York
$6.26K -$1.68K -34 -17%
CSS
54
Cubist Systematic Strategies
Connecticut
$5.14K +$6.83K +138 New
NFSG
55
Newbridge Financial Services Group
Florida
$3.72K – – –
Comerica Bank
56
Comerica Bank
Texas
$3.22K +$890 +18 +26%
NA
57
NewEdge Advisors
Louisiana
$3.16K +$4.2K +85 New
ACA
58
American Capital Advisory
Idaho
$2.64K – – –
Macquarie Group
59
Macquarie Group
Australia
$2.24K +$2.97K +60 New
JP Morgan Chase
60
JP Morgan Chase
New York
$1.12K -$23.9K -484 -94%
BNP Paribas Financial Markets
61
BNP Paribas Financial Markets
France
$993 -$28.2K -571 -95%
CC
62
Cypress Capital
Tennessee
$893 +$1.19K +24 New
KFS
63
Kelly Financial Services
Massachusetts
$620 – – –
Northwestern Mutual Wealth Management
64
Northwestern Mutual Wealth Management
Wisconsin
$620 – – –
HI
65
Harbour Investments
Wisconsin
$544 – – –
Osaic Holdings
66
Osaic Holdings
Arizona
$471 – – –
New York State Common Retirement Fund
67
New York State Common Retirement Fund
New York
$372 -$19.1K -387 -97%
SS
68
Sunbelt Securities
Texas
$294 – – –
AAP
69
Arax Advisory Partners
Colorado
$267 +$346 +7 New
AAG
70
Armstrong Advisory Group
Massachusetts
$149 – – –
IA
71
IFP Advisors
Florida
$124 – – –
IC
72
Innealta Capital
Texas
$61 +$99 +2 New
FFA
73
Farther Finance Advisors
California
$44 +$49 +1 New
Renaissance Technologies
74
Renaissance Technologies
New York
– -$518K -9,134 Closed
N
75
Nuveen
North Carolina
– -$277K -4,878 Closed
1 2
3
4

CUE Hedge Fund Activity: Q2 2024 in Review

75 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2024, worth a combined $17.1M — down 45% from $31M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new CUE positions and 20 closed out — a net gain of 1 holder — while 14 added to existing stakes and 22 trimmed.

The largest buyer was Good Life Advisors, adding an estimated $371K. The largest seller was BlackRock, cutting an estimated $2.45M.

  • 75 institutional investors held Cue Biopharma (CUE) as of Q2 2024, up from 74 in Q1 2024.
  • Funds reported $17.1M of Cue Biopharma stock for Q2 2024, down 45% quarter-over-quarter.
  • 21 funds opened new Cue Biopharma positions in Q2 2024 and 20 closed out, a net change of +1 holder.
  • The largest Cue Biopharma buyer in Q2 2024 was Good Life Advisors, an estimated $371K added.
  • The largest Cue Biopharma seller in Q2 2024 was BlackRock, an estimated $2.45M sold.

Based on aggregated 13F filings for Q2 2024.